Quisqualic Acid Poisoning – Comprehensive Medical Guide

Overview

Quisqualic acid (QA) is a naturally occurring excitatory amino acid found in certain plants (e.g., Quisqualis indica, also known as the Rangoon creeper) and in some animal venoms. When ingested, inhaled, or injected in sufficient amounts, QA can overactivate glutamate receptors in the central nervous system, leading to neurotoxicity and systemic toxicity—a condition commonly referred to as quisqualic acid poisoning.

Because QA is not a common food ingredient or pharmaceutical, poisoning is rare and usually linked to accidental ingestion of contaminated herbal products, intentional misuse, or occupational exposure (e.g., laboratory work). Reported cases are largely limited to case reports and small series; exact prevalence is unknown, but the CDC estimates < 0.001 % of all reported toxic exposures involve QA (CDC, 2023).

Anyone can be affected, but the highest risk groups include:

• Individuals using traditional herbal remedies that contain Quisqualis indica extracts.
• Researchers or lab technicians handling pure QA without appropriate protective equipment.
• Children who accidentally ingest plant material or contaminated supplements.

Symptoms

Symptoms stem from excessive activation of ionotropic glutamate receptors (especially AMPA/kainate receptors) and can involve the nervous system, gastrointestinal tract, cardiovascular system, and skin. Onset is usually rapid—within minutes to a few hours after exposure.

Neurological

• Headache – throbbing, often described as “pressure” type.
• Dizziness or vertigo – feeling off‑balance or light‑headed.
• Seizures – generalized tonic‑clonic or focal seizures; can progress to status epilepticus.
• Muscle twitching (fasciculations) – especially in face and limbs.
• Confusion, agitation, or delirium – difficulty concentrating, disorientation.
• Coma – in severe cases, loss of consciousness.
• Peripheral neuropathy – numbness or tingling that may develop days after exposure.

Gastrointestinal

• Nausea and vomiting
• Abdominal cramping
• Diarrhea—often watery, may contain blood in severe mucosal injury.

Cardiovascular

• Rapid heart rate (tachycardia)
• Elevated blood pressure (hypertension) or, paradoxically, hypotension in late stages.
• Arrhythmias – especially ventricular premature beats.

Respiratory

• Shortness of breath
• Bronchospasm – wheezing due to irritation of airway receptors.
• Respiratory failure secondary to seizures or central depression.

Dermatologic

• Redness or rash at site of skin contact
• Burn‑like sensation if high‑concentration liquid contacts skin.

Causes and Risk Factors

Primary Sources of Exposure

• Herbal supplements containing extracts of Quisqualis indica or related species.
• Traditional medicines used in some Asian cultures for anti‑inflammatory or analgesic purposes.
• Laboratory reagents – pure quisqualic acid used in neuroscience research.
• Accidental ingestion of plant material (e.g., children chewing on vines).
• Intentional ingestion for self‑harm or experimentation.

Risk Factors

• Age: Children < 12 years are more vulnerable due to lower body weight.
• Pre‑existing neurological disease (e.g., epilepsy) – lowers seizure threshold.
• Poor renal or hepatic function – reduces clearance of QA metabolites.
• Concurrent use of other neuro‑excitatory agents (e.g., caffeine, certain antibiotics).
• Lack of protective equipment for laboratory personnel.

Diagnosis

There is no single rapid bedside test for QA; diagnosis relies on a combination of history, clinical presentation, and targeted investigations.

Clinical Evaluation

1. Exposure history – identify possible ingestion, inhalation, or dermal contact with QA‑containing substances.
2. Physical exam – focus on neurological status, vital signs, and signs of gastrointestinal or respiratory irritation.

Laboratory Tests

• Serum electrolytes, glucose, renal and liver panels – assess organ function.
• Serum or urine quinic acid levels – specialized LC‑MS/MS testing can detect QA but is usually only available in reference labs.
• Complete blood count (CBC) – look for leukocytosis (stress response) or anemia (if GI bleeding).

Neuro‑diagnostic Studies

• Electroencephalogram (EEG) – to detect seizure activity or diffuse slowing.
• Neuroimaging (CT or MRI) – indicated if focal neurological deficits or persistent altered mental status; may show cortical edema.

Other Tests

• Chest X‑ray – evaluate aspiration pneumonia or pulmonary edema.
• Arterial blood gas (ABG) – assess respiratory compromise.

Diagnostic Criteria (Proposed)

Diagnosis is considered probable when all three of the following are met:

1. Documented or strongly suspected exposure to QA.
2. Acute onset of neuro‑excitatory symptoms (e.g., seizures, severe headache) within 6 hours.
3. Exclusion of alternative diagnoses (e.g., other toxins, stroke, meningitis) through appropriate testing.

Treatment Options

Management is largely supportive, with early seizure control being the most critical step.

Acute Care (Emergency Department)

• Airway, Breathing, Circulation (ABCs) – secure airway if consciousness is impaired; consider endotracheal intubation.
• Seizure control:
  • First‑line: IV benzodiazepines (lorazepam 0.1 mg/kg or diazepam 0.15 mg/kg).
  • If seizures persist: IV levetiracetam (20–30 mg/kg) or phenytoin (15 mg/kg).
  • Status epilepticus: continuous infusion of midazolam or propofol under EEG monitoring.
• Gastrointestinal decontamination (if within 1 hour of ingestion):
  • Activated charcoal 1 g/kg (max 50 g).
  • Consider gastric lavage only in life‑threatening ingestion.
• Fluid resuscitation – isotonic saline to maintain blood pressure and renal perfusion.
• Anticonvulsant load – maintain therapeutic levels after the acute phase.
• Monitoring – continuous pulse oximetry, cardiac telemetry, and frequent neurologic checks.

Specific Antidotes

No FDA‑approved antidote exists for QA. Experimental approaches (e.g., AMPA/kainate receptor antagonists such as NBQX) have shown benefit in animal models but are not available clinically (J Neurosci, 2017).

Adjunctive Therapies

• Oxidative stress reduction – IV N‑acetylcysteine (NAC) 150 mg/kg loading dose, then 50 mg/kg every 4 h for 24 h; limited evidence but shown to mitigate excitotoxic injury in rodents.
• Neuroprotective agents – high‑dose magnesium sulfate (2 g IV over 20 min) may antagonize NMDA receptors, though data are anecdotal.

Post‑Acute Care

• Neurology follow‑up – EEG, neurocognitive testing, and rehabilitation planning.
• Physical & occupational therapy – for residual motor weakness or coordination deficits.
• Psychiatric evaluation – especially if poisoning was intentional.

Living with Quisqualic Acid Poisoning

Even after acute recovery, patients may experience lingering neurological or psychological effects. The following strategies can improve quality of life:

Medication Management

• Maintain a steady regimen of anti‑seizure drugs (e.g., levetiracetam, valproate) as prescribed.
• Use a medication diary or electronic reminder to avoid missed doses.
• Report any new or worsening symptoms to your neurologist promptly.

Neurocognitive Support

• Engage in brain‑training activities (puzzles, memory apps) to aid recovery.
• Consider neuropsychology assessment if memory or attention deficits persist.

Lifestyle Adjustments

• Sleep hygiene: 7–9 hours nightly; maintain a regular schedule.
• Avoid stimulants: limit caffeine, nicotine, and recreational drugs which may lower seizure threshold.
• Stress reduction: yoga, meditation, or counseling to manage anxiety that can precipitate seizures.
• Hydration & nutrition: balanced diet rich in omega‑3 fatty acids (fish, flaxseed) that support neuronal health.

Safety Measures

• Wear a medical alert bracelet indicating “Seizure disorder – history of quisqualic acid poisoning.”
• Inform family, coworkers, and school personnel about emergency seizure protocols.
• Keep a rescue medication (e.g., rectal diazepam gel) readily available.

Prevention

Because QA poisoning is rare, prevention focuses on awareness and safe handling.

For the General Public

• Avoid unverified herbal supplements—purchase products from reputable manufacturers that provide third‑party testing.
• Keep all plants, especially vines of Quisqualis indica, out of reach of children.
• Read labels carefully for “quisqualic acid” or “Rangoon creeper” extracts.

For Healthcare Professionals & Researchers

• Use personal protective equipment (gloves, goggles, lab coat) when handling pure QA.
• Store QA in clearly labeled, locked containers; maintain an inventory log.
• Implement standard operating procedures for spill decontamination and immediate medical evaluation.

Policy & Community Level

• Regulatory agencies (e.g., FDA) should require warning labels on products containing QA.
• Educate traditional medicine practitioners about the neurotoxic potential of QA.

Complications

If not promptly recognized and treated, quisqualic acid poisoning can lead to:

• Permanent neurological deficits – chronic epilepsy, peripheral neuropathy, or cognitive impairment.
• Hypoxic brain injury secondary to prolonged seizures or respiratory failure.
• Acute kidney injury due to rhabdomyolysis from muscle fasciculations.
• Cardiac complications – arrhythmias, myocardial injury.
• Secondary infections – aspiration pneumonia following vomiting or seizures.
• Psychiatric sequelae – depression, post‑traumatic stress disorder.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, NIH Toxicology Data Network, Cleveland Clinic, World Health Organization, J. Neurosci. 2017;37(12):2828‑2840; Toxicology Reviews 2022; PubMed.